2.6 Secondary Coagulation, Fibrinolysis & Anticoagulant Monitoring

Secondary Coagulation, Fibrinolysis & Anticoagulant Monitoring

Quick Answer: Secondary hemostasis involves the enzymatic coagulation cascade, whose ultimate goal is to stabilize the fragile platelet plug with a robust fibrin network. The PT/INR test monitors the extrinsic pathway, while the aPTT test monitors the intrinsic pathway.

The Coagulation Cascade

The coagulation cascade is a highly regulated series of enzymatic amplifying reactions. Most coagulation factors are serine proteases synthesized by the liver, circulating in the blood as inactive zymogens until activated. The cascade consists of the Extrinsic and Intrinsic pathways, which converge into the Common pathway to generate thrombin.

1. Extrinsic Pathway (Tissue Factor Pathway)

This is the primary physiological initiator of coagulation in the body.

• Triggered by: Severe vascular injury that exposes Tissue Factor (Factor III), an integral membrane protein found on subendothelial fibroblasts and smooth muscle cells.
• Key Factor: Factor VII.
• Reaction Sequence: Exposed Tissue Factor binds directly to circulating Factor VII in the presence of calcium, activating it (VIIa). The TF-VIIa-Calcium complex then rapidly activates Factor X, funneling directly into the common pathway. Because it bypasses many steps, this pathway is very fast (measured in seconds).

2. Intrinsic Pathway (Contact Activation Pathway)

All components required for this pathway are intrinsic to the circulating blood.

• Triggered by: Contact of blood with a negatively charged surface (in vivo, subendothelial collagen; in vitro, glass or silica in a lab tube).
• Key Factors: The contact factors (XII, Prekallikrein, High Molecular Weight Kininogen), followed by XI, IX, and VIII.
• Reaction Sequence: Factor XII is activated to XIIa upon contact. XIIa activates XI to XIa. XIa activates IX to IXa. Finally, Factor IXa forms a complex with Factor VIIIa (acting as a critical cofactor), Calcium, and Platelet Phospholipid. This assembly is called the TENase complex, and its sole job is to activate Factor X.

3. Common Pathway

• Where the pathways converge: Both the extrinsic and intrinsic pathways converge at the activation of Factor X.
• Key Factors: X, V, II (Prothrombin), I (Fibrinogen).
• Reaction Sequence: Factor Xa forms a complex with Factor Va (cofactor), Calcium, and Platelet Phospholipid. This assembly is called the Prothrombinase complex. It rapidly cleaves Prothrombin (Factor II) into the highly active enzyme Thrombin (Factor IIa).
• Fibrin Formation: Thrombin is the central regulatory enzyme of hemostasis. It cleaves small peptides from soluble Fibrinogen (Factor I), converting it into insoluble Fibrin monomers that spontaneously polymerize. Finally, Thrombin activates Factor XIII (Fibrin Stabilizing Factor), which covalently cross-links the fibrin polymers to form a hardened, stable clot.

Laboratory Coagulation Assays

All coagulation testing requires plasma collected in a Sodium Citrate (light blue top) tube. Citrate binds calcium, halting the cascade to prevent clotting in the tube. When the assay is performed, calcium is added back in to start the timer. The ratio of blood to anticoagulant must be strictly 9:1; an underfilled tube will falsely prolong clotting times.

Vitamin K Dependent Factors & Warfarin Therapy

Factors II, VII, IX, and X (as well as regulatory Proteins C and S) are synthesized in the liver but require Vitamin K for the addition of a carboxyl group (gamma-carboxylation). This carboxyl group allows the factors to bind calcium and localize to phospholipid surfaces on platelets, which is essential for their function.

• Warfarin (Coumadin) is an oral anticoagulant that acts as a Vitamin K antagonist, blocking the recycling of Vitamin K. This leads to the production of non-functional factors.
• Factor VII has the shortest half-life in plasma (around 4-6 hours). Therefore, when a patient begins Warfarin therapy, Factor VII depletes first. This is why the PT assay (which relies on Factor VII) is uniquely sensitive to Warfarin and is the exclusive test used for monitoring.

Fibrinolysis & D-Dimer

Once the damaged vessel is healed, the fibrin clot becomes an obstruction and must be removed. This process is called fibrinolysis.

1. Endothelial cells slowly release Tissue Plasminogen Activator (tPA).
2. tPA binds to the clot and converts circulating Plasminogen into the active, powerful enzyme Plasmin.
3. Plasmin enzymatically digests and systematically chops up the fibrin clot.
4. When Plasmin digests cross-linked fibrin (fibrin that has been stabilized by Factor XIII), it yields specific breakdown fragments known as D-dimers.

Clinical Utility of the D-Dimer Assay

• D-dimer is an excellent, highly specific biochemical marker of active thrombosis and fibrinolysis. If there is no cross-linked fibrin clot being broken down in the body, the D-dimer level will be near zero.
• It is used primarily for its incredibly high negative predictive value. A normal (negative) D-dimer safely and effectively rules out Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in low-to-moderate risk patients, avoiding the need for expensive imaging.
• An elevated D-dimer indicates a clot is present and actively being degraded. This is a critical diagnostic criteria for Disseminated Intravascular Coagulation (DIC), but D-dimers can also be nonspecifically elevated in normal pregnancy, post-surgery, trauma, or severe inflammation.